Recent Advances in the Treatment of Advanced HER2+ Breast Cancer: SABCS 2024 - Episode 12
SABCS Highlights and Future Directions in the Treatment of Breast Cancer
Panelists discuss how the continued evolution of HER2-directed therapies, particularly the expanding role of trastuzumab deruxtecan (T-DXd) across different breast cancer settings, has transformed the treatment landscape, while emphasizing the importance of appropriate patient selection, optimal sequencing strategies, and the need for education around early adoption of promising therapies in community practice settings.
Video content above is prompted by the following:
Before we wrap up, I’d like to hear your final thoughts and reflections on the strides we made throughout 2024—including new/exciting data presented at SABCS 2024.
- Let’s consider what opportunities/what we are looking forward to in 2025. Points to consider:
- Which developments stand out as pivotal in shaping clinical practice?
- What are you most excited about in 2025?
- What areas are primed for significant progress?
- What do you hope to achieve in the coming year?
- What advice would you offer to community oncologists who remain hesitant to use T-DXd in appropriate candidates or who prefer to reserve it for later lines of therapy?
Related Content:
